A Multicenter Phase 2 Single Arm Study of Cabozantinib in Patients with Advanced or Unresectable Renal Cell Carcinoma Pre-Treated with One Immune-Checkpoint Inhibitor: the BREAKPOINT Trial (Meet-Uro Trial 03).
TUMORI JOURNAL（2023）
关键词
Renal cell carcinoma,TKI,immune-checkpoint inhibitor,treatment sequencing,anti-VEGF,combination immunotherapy
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要